The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis
Open accessAbstract
Importance: Depressive disorders (DDs), anxiety disorders (ADs), obsessive-compulsive disorder (OCD), and posttraumatic stress disorder (PTSD) are common mental disorders in children and adolescents. Objective: To examine the relative efficacy and safety of selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and placebo for the treatment of DD, AD, OCD, and PTSD in children and adolescents. Data Sources: PubMed, EMBASE, PsycINFO, Web of Science, and Cochrane Database from inception through August 7, 2016. Study Selection: Published and unpublished randomized clinical trials of SSRIs or SNRIs in youths with DD, AD, OCD, or PTSD were included. Trials using other antidepressants (eg, tricyclic antidepressants, monoamine oxidase inhibitors) were excluded. Data Extraction and Synthesis: Effect sizes, calculated as standardized mean differences (Hedges g) and risk ratios (RRs) for adverse events, were assessed in a random-effects model. Main Outcomes and Measures: Primary outcomes, as defined by authors on preintervention and postintervention data, mean change data, and adverse event data, were extracted independently by multiple observers following PRISMA guidelines. Results: Thirty-six trials were eligible, including 6778 participants (3484 [51.4%] female; mean [SD] age, 12.9 [5.1] years); 17 studies for DD, 10 for AD, 8 for OCD, and 1 for PTSD. Analysis showed that SSRIs and SNRIs were significantly more beneficial compared with placebo, yielding a small effect size (g = 0.32; 95% CI, 0.25-0.40; P < .001). Anxiety disorder (g = 0.56; 95% CI, 0.40-0.72; P < .001) showed significantly larger between-group effect sizes than DD (g = 0.20; 95% CI, 0.13-0.27; P < .001). This difference was driven primarily by the placebo response: patients with DD exhibited significantly larger placebo responses (g = 1.57; 95% CI, 1.36-1.78; P < .001) compared with those with AD (g = 1.03; 95% CI, 0.84-1.21; P < .001). The SSRIs produced a relatively large effect size for ADs (g = 0.71; 95% CI, 0.45-0.97; P < .001). Compared with participants receiving placebo, patients receiving an antidepressant reported significantly more treatment-emergent adverse events (RR, 1.07; 95% CI, 1.01-1.12; P = .01 or RR, 1.49; 95% CI, 1.22-1.82; P < .001, depending on the reporting method), severe adverse events (RR, 1.76; 95% CI, 1.34-2.32; P < .001), and study discontinuation due to adverse events (RR, 1.79; 95% CI, 1.38-2.32; P < .001). Conclusions and Relevance: Compared with placebo, SSRIs and SNRIs are more beneficial than placebo in children and adolescents; however, the benefit is small and disorder specific, yielding a larger drug-placebo difference for AD than for other conditions. Response to placebo is large, especially in DD. Severe adverse events are significantly more common with SSRIs and SNRIs than placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, current therapeutic tools have failed to reduce the prevalence of depression, with many patients not responding to, and most having significant side effects from, first-line treatments such as selective serotonin reuptake inhibitors (SSRIs)”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Locher et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“While this reduction does not lower glutamate levels to the same concentration as healthy controls, it has been shown that antidepressant-treated glutamate levels are positively correlated with Hamilton Depression Rating Scale scores187.”
From Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications (2022) · cites this paper as [187]
In the citing paper
“Antidepressants are indicated and used for depressive disorders, anxiety disorders, posttraumatic stress disorder, premenstrual dysphoric disorder, obsessive-compulsive disorder, bulimia nervosa, and binge-eating disorder, among others.[3][4][5]”
From Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review (2019) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,762
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Flagged first, then by citations
Research works printed but not linked: 2
- [25]Hedges LV Olkin I Statistical methods for meta-analysis Academic press 2014
- [75]Rutherford BR Sneed JR Tandler JM Rindskopf D Peterson BS Roose SP Deconstructing pediatric depression trials: An analysis of the effect of expectancy and theurapeutic contact J Am Acad Child Adolesc Psychiatry 2011 50 8 782 795 21784298 PMC3143372
Cited by
Sorted by citations
Items 101–200 of 359
Lithium Treatment in Children and Adolescents
Duffy, A., & Grof, P. (2018) · Pharmacopsychiatry · doi:10.1055/a-0575-4179 · Cited by 22
A Systematic Review of Pharmacologic Treatments for School Refusal Behavior
Londono Tobon, A., Reed, M. O., Taylor, J. H., & Bloch, M. H. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0160 · Cited by 22
Pittenger, C., Brennan, B. P., Koran, L. M., Mathews, C. A., Nestadt, G., Pato, M. T., Phillips, K. A., Rodríguez, C. I., Simpson, H. B., Skapinakis, P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113853 · Cited by 22
Börner, C., Urban, G., Beaulieu, L., Sollmann, N., Krieg, S. M., Straube, A. M., Renner, T., Schandelmaier, P., Lang, M., Lechner, M. F., et al. (2021) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2021.02.008 · Cited by 21
Lomas, T., Bartels, M., van de Weijer, M. P., Pluess, M., Hanson, J. A., & VanderWeele, T. J. (2022) · Emotion Review · doi:10.1177/17540739221114109 · Cited by 24
Pilc, A., Machaczka, A., Kawalec, P., Smith, J. L., & Witkin, J. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2111415 · Cited by 21
Anxiety and Depression Treatment in Primary Care Pediatrics
Lester, T. R., Herrmann, J. E., Bannett, Y., Gardner, R. M., Feldman, H. M., & Huffman, L. C. (2023) · PEDIATRICS · doi:10.1542/peds.2022-058846 · Cited by 21
Twenty years of progress in paediatric psychopharmacology: accomplishments and unmet needs
Vitiello, B., & Davico, C. (2018) · Evidence Based Mental Health · doi:10.1136/ebmental-2018-300040 · Cited by 21
Legenbauer, T., Kirschbaum-Lesch, I., Jörke, C., Kölch, M., Reis, O., Berger, C., Dück, A., Schulte-Markwort, M., Becker-Hebly, I., Bienioschek, S., et al. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.0103 · Cited by 20
Fan, L., Zeng, P., Wang, X., Mo, X., Ma, Q., Zhou, X., Yuan, N., Liu, Y., Xue, Z., Huang, J., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155660 · Cited by 21
Cervin, M., Storch, E. A., Piacentini, J., Birmaher, B., Compton, S. N., Albano, A. M., Gosch, E., Walkup, J. T., & Kendall, P. C. (2020) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13124 · Cited by 18
Stefánsdóttir, Í. H., Ivarsson, T., & Skarphedinsson, G. (2023) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2075460 · Cited by 19
Luccarelli, J., McCoy, T. H., York, T., Baldwin, I., Fricchione, G. L., Fuchs, C., & Smith, J. R. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.07.004 · Cited by 19
Nonpharmacological Interventions for Pediatric Migraine: A Network Meta-analysis
Koechlin, H., Kossowsky, J., Lam, T. L., Barthel, J., Gaab, J., Berde, C. B., Schwarzer, G., Linde, K., Meißner, K., & Locher, C. (2021) · PEDIATRICS · doi:10.1542/peds.2019-4107 · Cited by 19
Self-citationMotta, L. S., Gosmann, N. P., Costa, M. D. A., Jaeger, M. D. B., Frozi, J., Grevet, L. T., Spanemberg, L., Manfro, G. G., Cuijpers, P. J., Pine, D. S., et al. (2023) · BMJ Mental Health · doi:10.1136/bmjment-2022-300630 · Cited by 24
Self-citationThe multifaceted effects of fluoxetine treatment on cognitive functions
Ampuero, E., Luarte, A., Flores, F. S., Soto, A. I., Pino, C. H., Silva, V., Erlandsen, M., Concha, T., & Wyneken, Ú. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1412420 · Cited by 23
Holtmann, M. H., Mokros, L., Kirschbaum‐Lesch, I., Kölch, M. G., Plener, P. L., Ruckes, C., Schulte‐Markwort, M., & Legenbauer, T. (2018) · Trials · doi:10.1186/s13063-018-2949-0 · Cited by 19
Wang, S., Yao, Z., Zhao, C.-B.-W., Ding, Y.-S., JingLUO, Bian, L.-H., Li, Q., Wang, X., Shi, J., Guo, J., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113452 · Cited by 19
Pollak, U., Bronicki, R. A., Achuff, B.-J., & Checchia, P. A. (2019) · Journal of Intensive Care Medicine · doi:10.1177/0885066619871432 · Cited by 18
Singh, K., Bhatia, R., Kumar, B., Singh, G., & Monga, V. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211102154311 · Cited by 18
Reinodt, S., Haglund, E., Bremander, A., Jarbin, H., & Larsson, I. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19052894 · Cited by 20
Zhou, C., Chen, Y., Xue, S., Shi, Q., Guo, L., Yu, H., Xue, F., Cai, M., Wang, H., & Peng, Z. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14287 · Cited by 17
Liking of salt is associated with depression, anxiety, and stress
Ferraris, C., Scarlett, C. J., Bucher, T., & Beckett, E. (2023) · Chemical Senses · doi:10.1093/chemse/bjad038 · Cited by 18
The placebo and its effects: A psychoneuroendocrinological perspective
Gaab, J. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.08.008 · Cited by 18
Li, Y., Huang, J., He, Y., Yang, J., Lv, Y., Liu, H., Liang, L., Li, H., Zheng, Q., & Li, L. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0022 · Cited by 18
Zhan, Y., Xia, J., & Wang, X. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2019.1684276 · Cited by 21
Dysregulation, Catastrophic Reactions, and the Anxiety Disorders
Walkup, J. T., Friedland, S. J., Peris, T. S., & Strawn, J. R. (2021) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2020.10.011 · Cited by 20
Serrander, M., Bremander, A., Jarbin, H., & Larsson, I. (2021) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2021.1909128 · Cited by 18
Fluvoxamine Suppressed Oxidative Stress associated with Tissue Erosion
Abdulqader, S. W., Faisal, I., Saeed, M. G., & Merkhan, M. M. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00136 · Cited by 17
Gao, W., Long, D.-D., Pan, T., Hu, R. M., Chen, D., Mao, Y., Chai, X., Jin, Y., Zhang, Z., & Wang, D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115293 · Cited by 17
Ren, J., Zhang, Y., Pan, H., Shi, R., Zhu, H., Yang, R., Zhang, L., Chen, B., Zhu, T., Lu, X., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111405 · Cited by 18
Jarbin, H., Höglund, K., Skarphéðinsson, G., & Bremander, A. (2021) · Clinical Child Psychology and Psychiatry · doi:10.1177/13591045211000782 · Cited by 19
Clinical pharmacological innovation in the treatment of depression
Witkin, J. M., Golani, L. K., & Smith, J. L. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2198703 · Cited by 16
Strekalova, T. V., Radford‐Smith, D. E., Dunstan, I. K., Вячеславовна, Г. А., Svirin, E. P., Sheveleva, E., Burova, A., Morozov, S., Lyundup, A. V., Berger, G. E., et al. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100646 · Cited by 17
Wang, H., Li, S., Zhang, J., Peng, W., Li, T., & Zhang, J. (2024) · European journal of medical research · doi:10.1186/s40001-024-02006-z · Cited by 16
Wang, W., Wang, D., Zhao, D., Xu, L., Jiang, S., Zhang, Y., Cui, M., Liu, J., Meng, F., Liu, C., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03093-6 · Cited by 16
Involvement of muscarinic receptor mechanisms in antidepressant drug action.
Witkin, J., Smith, J., Golani, L., Brooks, E., & Martin, A. E. (2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.03.003 · Cited by 15
Taipale, H. T., Niederkrotenthaler, T., Helgesson, M., Sijbrandij, M., Berg, L., Tanskanen, A. J., & Mittendorfer‐Rutz, E. (2020) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-020-01951-4 · Cited by 16
Eating Behavior and the Evolutionary Perspective on Anorexia Nervosa
Södersten, P., Brodin, U., Zandian, M., & Bergh, C. E. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00596 · Cited by 16
Mohamadi, S., Ahmadzad-Asl, M., Nejadghaderi, S. A., Kermani, R. J. N., Mirbehbahani, S. H., Sinyor, M., Richter, M. A., & Davoudi, F. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221115029 · Cited by 18
Safer, D. J., & ZITO, J. M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00705 · Cited by 17
Ahmadimanesh, M., Balarastaghi, S., Rashedinia, M., & Robati, R. Y. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05550-8 · Cited by 15
Zhang, B., Yang, L., Sun, W., Xu, P., Ma, H., & Abdullah, A. B. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100683 · Cited by 14
Meranzin hydrate elicits antidepressant effects and restores reward circuitry
Liu, X., Zhou, J., Zhang, T., Chen, K., Xu, M., Wu, L., Liu, J., Huang, Y., Nie, B., Shen, X., et al. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112898 · Cited by 14
Mossman, S. A., Mills, J. A., Walkup, J. T., & Strawn, J. R. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0195 · Cited by 14
Moody kids years later: Long-term outcomes of youth from the Omega-3 and therapy (OATS) studies
Fristad, M. A., Roley‐Roberts, M. E., Black, S. R., & Arnold, L. E. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.115 · Cited by 14
Reily, N. M., Tang, S., Negrone, A., Gan, D. Z. Q., Sheanoda, V., & Christensen, H. M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284057 · Cited by 17
Poweleit, E. A., Vaughn, S. E., Desta, Z., Dexheimer, J. W., Strawn, J. R., & Ramsey, L. B. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3184 · Cited by 13
Antidepressant-induced membrane trafficking regulates blood-brain barrier permeability
Du, W., Chen, H., Gróf, I., Lemaitre, L., Bocsik, A., Perdyan, A., Mieczkowski, J., Deli, M. A., Hortobágyi, T., Wan, Q., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02626-1 · Cited by 14
Hines, L. J., Wilke, R. A., Myers, R. A., Mathews, C. A., Liu, M., Baye, J. F., Petry, N., Cicali, E. J., Duong, B. Q., Elwood, E. N., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13822 · Cited by 15
Expert recommendations for Germany’s integration of psychedelic-assisted therapy
Rosal, S. P., Torre, J. T. L., Birnkammer, S., Chernoloz, O., Williams, M. T., & Faber, S. C. (2024) · BMC Medical Education · doi:10.1186/s12909-024-06141-3 · Cited by 13
Wu, T., Song, F., Cao, W., Liu, C., & Jia, S. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06941-x · Cited by 17
The Potential Role of Serotonergic Hallucinogens in Depression Treatment
Psiuk, D., Nowak, E., Cholewa, K., Łopuszańska, U., & Samardakiewicz, M. (2021) · Life · doi:10.3390/life11080765 · Cited by 12
Gastrointestinal adverse events associated with SNRIs: A FAERS-based pharmacovigilance study
Lin, J., Wei, S., Peng, Y., Liang, C., Jiao, W., Ji, Y., Deng, Y., Yan, F., & Xi, J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119484 · Cited by 12
Witt, K., Madsen, T., Berk, M., Dean, O. M., Chanen, A. M., McGorry, P. D., Cotton, S., Davey, C. G., & Hetrick, S. E. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867421998763 · Cited by 12
A novel strategy for designing the magic shotguns for distantly related target pairs
Luo, Y., Wang, P., Mou, M., Zheng, H., Hong, J., Tao, L., & Zhu, F. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac621 · Cited by 13
Otter, M., Kothgassner, O. D., Lepuschütz, L., Drahos, S., & Plener, P. L. (2024) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-023-00684-x · Cited by 14
Gasotransmitter‐Nanodonor for Spatial Regulation of Anxiety‐Like Behavior and Bone Metastasis
Zhang, J.-Q., Wang, P., Zhou, M.-N., Wang, Y., Li, L.-L., Guo, J., Zhu, X.-L., Qing, X., Qian, J.-Y., Huang, X.-W., et al. (2025) · Advances in Materials · doi:10.1002/adma.202416481 · Cited by 13
Mi, Y., Chen, L., Zheng, H., Wu, Y., Hou, Y., Hu, J., Mao, J., Dai, N., Li, X., Lou, Z., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1587742 · Cited by 12
Improved Serotonin Measurement with Fast-Scan Cyclic Voltammetry: Mitigating Fouling by SSRIs
Stucky, C. S., & Johnson, M. A. (2022) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/ac5ec3 · Cited by 13
Wallman, E. J., Segrave, R. A., Gordon, M. S., Fraser, M. J. O. B., Pavlou, C., & Melvin, G. A. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.057 · Cited by 12
Patriota, L. L. D. S., de Lima, B. R. F., Marinho, A. D. O., da Costa, J. A., Coelho, L. C. B. B., Paiva, P. M. G., da Rosa, M. M., & Napoleão, T. H. (2023) · Brain Disorders · doi:10.1016/j.dscb.2023.100066 · Cited by 12
Pruneti, C. A., & Guidotti, S. (2023) · Nutrients · doi:10.3390/nu15102306 · Cited by 12
Guo, W., Gao, Y., Jiang, W., Li, C., Lin, F., Zhu, H., Wang, H., Ye, L., Qi, J. G., Cen, X., et al. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.10.008 · Cited by 12
Systemic neuro-dysregulation in depression: Evidence from genome-wide association
Tubbs, J. D., Ding, J., Baum, L., & Sham, P. C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.08.007 · Cited by 12
Цейликман, В. Э., Fedotova, J., Tseilikman, O. B., Novak, J., Karpenko, M. N., Maistrenko, V. A., Lazuko, S. S., Belyeva, L. E., Kamel, M., Buhler, A. V., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119333 · Cited by 11
State of the Evidence for Use of Psychotropic Medications in School-Age Youth
Shahidullah, J. D., Roberts, H. J., Parkhurst, J. T., Ballard, R., Mautone, J. A., & Carlson, J. S. (2023) · Children · doi:10.3390/children10091454 · Cited by 11
Major challenges in youth psychopathology: treatment-resistant depression. A narrative review
Menculini, G., Cinesi, G., Scopetta, F., Cardelli, M., Caramanico, G., Balducci, P. M., Giorgi, F. D., Moretti, P., & Tortorella, A. A. V. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1417977 · Cited by 13
The Use of Antidepressants, Antipsychotics, and Stimulants in Youth Residential Care
Oerbeck, B., Øvergaard, K. R., Hjellvik, V., Lien, L., & Bramness, J. G. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0123 · Cited by 11
What’s in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology
Sultan, R. S., Correll, C. U., Zohar, J., Zalsman, G., & Veenstra-VanderWeele, J. M. (2018) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2018.05.024 · Cited by 11
Saunders, R., Suh, J. W., Buckman, J. E. J., John, A., Baou, C. E., Pilling, S., Lewis, G., Stott, J. C. H., Krebs, G., & Stringaris, A. K. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00207-x · Cited by 15
Morgan, A. J., Ross, A., Yap, M. B. H., Reavley, N. J., Parker, A. G., Simmons, M. B., Scanlan, F., & Jorm, A. F. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.13087 · Cited by 13
Current and Future Approaches to Pediatric Anxiety Disorder Treatment
Zugman, A., Winkler, A. M., Qamar, P., & Pine, D. S. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231037 · Cited by 16
Self-citationIto, T., Hiramatsu, Y., Uchida, M., Yoshimi, A., Mamiya, T., Mouri, A., Ozaki, N., & Noda, Y. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104826 · Cited by 12
Koechlin, H., Kharko, A., Probst, T., Pradela, J., Buechi, S., & Locher, C. (2021) · Frontiers in Pain Research · doi:10.3389/fpain.2021.750523 · Cited by 8
Self-citationSalam, R. A., Khan, M. H., Meerza, S. S. A., Das, J. K., Lewis-Watts, L., & Bhutta, Z. A. (2024) · Nature Medicine · doi:10.1038/s41591-023-02737-2 · Cited by 10
Bushnell, G., Brookhart, M. A., Gaynes, B. N., Compton, S. N., Dusetzina, S. B., & Stürmer, T. (2018) · Medical Care · doi:10.1097/mlr.0000000000000911 · Cited by 10
Management of Depression in Adolescents in Japan
Saito, T., Reines, E. H., Florea, I., & Dalsgaard, M. K. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0023 · Cited by 10
Pain, the unknown: epistemological issues and related clinical implications
Facco, E. (2021) · Minerva Anestesiologica · doi:10.23736/s0375-9393.21.15920-6 · Cited by 12
Tao, Q., Dang, J., Guo, H., Zhang, M., Niu, X., Kang, Y., Sun, J., Ma, L., Wei, Y., Wang, W., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.07.123 · Cited by 9
Ameringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 12
The development of the serotonergic and dopaminergic systems during chicken mid-late embryogenesis
Huang, X., Kuang, S., Applegate, T. J., Lin, T.-L., & Cheng, H. W. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110472 · Cited by 9
Shu, X., Tong, Y., & Yang, R. (2022) · International Journal of Food Science & Technology · doi:10.1111/ijfs.15745 · Cited by 9
Anderson, G. M., & Bruno-Pacella, I. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06276-5 · Cited by 9
Kolitsopoulos, F., Ramaker, S., Compton, S. N., Broderick, S., Orazem, J. P., Bao, W., Lokhnygina, Y. V., Marschall, K., & Chappell, P. B. (2023) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2022.0048 · Cited by 10
Henn, L., Zanta, N. C., Girardi, C. E. N., & Suchecki, D. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02164-1 · Cited by 9
Restoring the two pivotal fluoxetine trials in children and adolescents with depression
Gøtzsche, P. C., & Healy, D. (2022) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-210034 · Cited by 8
He, P., Lu, X., Zhong, M., Weng, H., Wang, J., Zhang, X., Jiang, C., Geng, F., Shi, Y., & Zhang, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1449202 · Cited by 8
Wang, X., Zhang, Z., Li, Y., Gao, Y., & Cao, Q.-J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120132 · Cited by 8
Dezfouli, R. A., Hosseinpour, A., Ketabforoush, S., & Daneshzad, E. (2024) · Middle East Current Psychiatry · doi:10.1186/s43045-024-00400-1 · Cited by 9
Parker, A. G., Markulev, C., Rickwood, D., Mackinnon, A. J., Purcell, R., Álvarez‐Jiménez, M., Yung, A. R., McGorry, P. D., Hetrick, S. E., & Jorm, A. F. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-034002 · Cited by 10
Yan, L., Wang, S., Zhao, L., Qiu, J., Zhou, L., Wang, W., Xu, X., Wang, D., Qiu, X., & Qin, D. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2471870 · Cited by 8
Young, J. N., Ramachandran, S., Freeman, A. J., Bentley, J. P., & Banahan, B. F. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221251 · Cited by 8
Omega-3 fatty acid supplementation for depression in children and adolescents
Campisi, S. C., Zasowski, C., Bradley-Ridout, G., Schumacher, A., Szatmári, P., & Korczak, D. J. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014803.pub2 · Cited by 12
Nasir, M., Li, F., Courley, S., Olten, B., & Bloch, M. H. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0030 · Cited by 7
Novel mechanism-based treatments for pediatric anxiety and depressive disorders
Sylvester, C. M., Luby, J. L., & Pine, D. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01709-x · Cited by 7
Self-citationRamsey, L. B., Aldrich, S. L., Poweleit, E. A., Prows, C. A., Martin, L. J., & Strawn, J. R. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0110 · Cited by 7
Westergren, T., Narum, S., & Klemp, M. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026089 · Cited by 7
Drivers of and Solutions for the Overuse of Antidepressant Medication in Pediatric Populations
Cosgrove, L., Morrill, Z., Yusif, M., Vaswani, A., Cathcart, S. C., Troeger, R., & Karter, J. M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00017 · Cited by 7
Latest thinking on antidepressants in children and young people
Dubicka, B., & Wilkinson, P. O. (2018) · Archives of Disease in Childhood · doi:10.1136/archdischild-2017-314075 · Cited by 7
Metadata
- Authors
- Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J.
- Affiliations
- University of Basel (CH)
- Boston Children's Hospital (US)
- Stanford University (US)
- National Institute of Mental Health (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Corresponding author
- Kossowsky, Joe
- ORCID
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2017-10-01
- Volume
- 74
- Issue
- 10
- Pages
- 1011
- ISSN
- 2168-622X (ISSN-L)
- PMC
- PMC5667359
- OpenAlex
- W2752088033
- Cited by
- 360
- References
- 90
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 50 · 2023: 42 · 2022: 37 · 2021: 46 · 2020: 44 · 2019: 48 · 2018: 30 · 2017: 3
- FWCI
- 23.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Psychiatry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (ZIA‐MH002781)
- U.S. National Library of Medicine (T15LM007092)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, children and adolescents, depression, anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, placebo response, adverse drug reactions, antidepressant efficacy, antidepressant safety, treatment-resistant depression, treatment-emergent mania, suicidal ideation
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Adolescent, Mental Disorders, Child, Female, Humans, Male, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
